Newton™ Soft Tissue Management Technology: 1st Surgeries Reported

Newton™, is an innovative soft tissue management technology that combines dynamic ligament balancing and real-time guidance to bring to life a personalized intraoperative solution designed to improve total knee replacement surgery outcomes and patient satisfaction.

First Surgeries

First surgeries were performed by Hari K. Parvataneni, MD, professor of orthopaedic surgery at the University of Florida, and James Huddleston III, MD, professor of orthopaedic surgery and chief of the adult reconstruction service at Stanford University Medical Center. According to Huddleston, “Soft tissue management is an area of opportunity for progression in orthopaedics, and Exactech is leading the way. Newton is a sophisticated technology that is designed to provide real-time, patient-specific insights to help easily optimize the soft tissue with the goal of achieving the best possible outcomes for total knee patients.”

What is Newston?

Newton is an innovative intra-articular device that engages the patient’s soft tissue to help surgeons execute a personalized, well-balanced total knee replacement. By capturing active balance data through the entire arc of motion with the patella in place, Newton seamlessly integrates with ExactechGPS’s connected platform to allow surgeons to visualize a predictive plan through operative insights, without the need for external soft tissue tensioners.

Remarks from Exactech Marketing

“We are excited to introduce this game-changing technology for total knee replacement surgery,” said Adam Hayden, Exactech’s chief marketing officer and senior vice president of Large Joints. “Newton is yet another example of Exactech pioneering innovations that provide orthopaedic surgeons with intelligent insights to make smart decisions throughout the journey of care.”

Newton is the company’s latest release within its Active Intelligence platform of smart solutions that help surgeons engage with patients and peers, solve challenges with predictive tools and optimize performance. The technology is in pilot launch in the US with expanded availability planned before the end of the year.

Surgeons can experience Newton and ExactechGPS first-hand at the AAOS Annual Meeting – Booth #1035 – Sept. 1 – 3, 2021, through live demonstrations.

SourceExactech

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version